XML 22 R13.htm IDEA: XBRL DOCUMENT
v3.23.3

Revenue (Notes) | 9 Months Ended
--- | ---
Sep. 30, 2023
Revenue from Contract with Customer [Abstract] |
Revenue from Contract with Customer [Text Block] | Revenue Revenue Recognition As part of the integration of our acquisition of Smiths Medical, we have now migrated to our new business unit structure of Consumables, Infusion Systems and Vital Care. The vast majority of our sales of products within these business units are made on a stand-alone basis to hospitals and distributors. Our revenues are recorded at the net sales price, which includes an estimate for variable consideration related to rebates, chargebacks and product returns. Revenue is typically recognized upon transfer of control of the products, which we deem to be at point of shipment. However, for purposes of revenue recognition for our software licenses and renewals, we consider the control of these products to be transferred to a customer at a certain point in time; therefore, we recognize revenue at the start of the applicable license term. Payment is typically due in full within 30 days of delivery or the start of the contract term. Revenue is recorded in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. We offer certain volume-based rebates to our distribution customers, which we record as variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time and our historical experience with each customer to estimate the most likely rebate amount. We also provide chargebacks to distributors that sell to end customers at prices determined under a contract between us and the end customer. Chargebacks are the difference between the prices we charge our distribution customers and the contracted prices we have with the end customer which are processed as credits to our distribution customers. In estimating the expected value of chargeback amounts in order to determine the transaction price, we use information available at the time, including our historical experience. We also warranty products against defects and have a policy permitting the return of defective products, for which we accrue and expense at the time of sale using information available at that time and our historical experience. We also provide extended service-type warranties, which we consider to be separate performance obligations. We allocate a portion of the transaction price to the extended service-type warranty based on its estimated relative stand-alone selling price, and recognize revenue over the period the warranty service is provided. Revenue Disaggregated The following table represents our revenues disaggregated by product line (in thousands):
| Three months ended September 30, |  | Nine months ended September 30,
Product line | 2023 |  | 2022 |  | 2023 |  | 2022
Consumables | 242,010 |  |  | 251,572 |  |  | 715,108 |  |  | 732,756 |
Infusion Systems | 148,981 |  |  | 161,555 |  |  | 463,836 |  |  | 448,426 |
Vital Care | 162,320 |  |  | 184,730 |  |  | 492,326 |  |  | 520,801 |
Total Revenues | $ | 553,311 |  |  | $ | 597,857 |  |  | $ | 1,671,270 |  |  | $ | 1,701,983 |
For the three and nine months ended September 30, 2023, net sales to Medline made up approximately 18% and 16% of total revenues, respectively. For the three and nine months ended September 30, 2022, net sales to Medline made up approximately 16% and 15% of total revenues, respectively. The following table represents our revenues disaggregated by geography (in thousands):
| Three months ended September 30, |  | Nine months ended September 30,
Geography | 2023 |  | 2022 |  | 2023 |  | 2022
United States | $ | 355,984 |  |  | $ | 376,691 |  |  | $ | 1,063,037 |  |  | $ | 1,088,348 |
Europe, the Middle East and Africa | 88,014 |  |  | 101,869 |  |  | 276,994 |  |  | 275,488 |
APAC | 59,064 |  |  | 66,569 |  |  | 177,719 |  |  | 191,847 |
Other Foreign | 50,249 |  |  | 52,728 |  |  | 153,520 |  |  | 146,300 |
Total Revenues | $ | 553,311 |  |  | $ | 597,857 |  |  | $ | 1,671,270 |  |  | $ | 1,701,983 |
Contract Balances The following table presents the changes in our contract balances for the nine months ended September 30, 2023 and 2022 (in thousands):
| Contract Liabilities
Beginning balance, January 1, 2023 | $ | (45,866) |
Equipment revenue recognized | 24,872 |
Equipment revenue deferred | (25,620) |
Software revenue recognized | 13,546 |
Software revenue deferred | (12,797) |
Government grant deferred income* | (944) |
Government grant recognized | 3,164 |
Other deferred revenue | (1,674) |
Other deferred revenue recognized | 4,748 |
Ending balance, September 30, 2023 | $ | (40,571) |
Beginning balance, January 1, 2022 | $ | (7,461) |
Fair value of acquired deferred revenue | (51,245) |
Equipment revenue recognized | 22,757 |
Equipment revenue deferred | (13,420) |
Software revenue recognized | 12,761 |
Software revenue deferred | (12,978) |
Government grant deferred income* | (3,434) |
Government grant recognized | 178 |
Other deferred revenue | (1,285) |
Other deferred revenue recognized | 3,488 |
Ending balance, September 30, 2022 | $ | (50,639) |
____________________________ *The government grant deferred income is amortized over the life of the related depreciable asset as a reduction to depreciation expense. Our contract liabilities are included in accrued liabilities or other long-term liabilities in our condensed consolidated balance sheet based on the expected timing of revenue recognition. As of September 30, 2023, revenue from remaining performance obligations is as follows:
| Recognition Timing
(in millions) | < 12 Months |  | > 12 Months
Equipment deferred revenue | $ | (16,448) |  |  | $ | (12) |
Software deferred revenue | (8,261) |  |  | (707) |
Government grant deferred income* | (1,451) |  |  | (10,548) |
Other deferred revenue** | (2,575) |  |  | (569) |
Total | $ | (28,735) |  |  | $ | (11,836) |
_________________________________ *The government grant deferred income is amortized over the life of the related depreciable asset as a reduction to depreciation expense. **Other deferred revenue includes pump development programs, purchased training and extended warranty.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org//606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration